Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-02-22
2005-02-22
Kifle, Bruck (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S221000, C540S557000, C540S567000
Reexamination Certificate
active
06858605
ABSTRACT:
The invention relates to new 2,3-benzodiazepine derivatives of formula (I), isomers and acid addition salts thereof and to pharmaceutical compositions containing the same, as well as to pharmaceutical compositions and methods of using the same suitable for treating conditions associated with muscle spasms, epilepsy, acute and chronic forms of neurodegenerative diseases as well as preventing, treating or alleviating the symptoms of acute and chronic inflammatory disorders.
REFERENCES:
patent: 4614740 (1986-09-01), Láng et al.
patent: 5536832 (1996-07-01), Andrási et al.
patent: 5756495 (1998-05-01), Hámori et al.
patent: 5795886 (1998-08-01), Anderson et al.
patent: 6200970 (2001-03-01), Ling et al.
patent: 0 699 677 (1996-03-01), None
patent: 2 311 779 (1997-10-01), None
patent: 9211262 (1992-07-01), None
patent: 9501357 (1995-01-01), None
patent: 9604283 (1996-02-01), None
patent: 9606606 (1996-03-01), None
patent: 9728135 (1997-08-01), None
patent: 9907707 (1999-02-01), None
patent: 9907708 (1999-02-01), None
patent: 0104122 (2001-01-01), None
Anderson et al. (Bioorganic & Medicinal Chemistry Letters 9 (1999), 1953-1956).*
Lipton et al.,The New England Journal of Medicine330, No. 9, pp. 613-622 (Mar. 3, 1994), published by the Massachusetts Medical Society, Boston, MA.
Goodman and Gilman's The Pharmacological Basis of Therapeutics, 10thedition(2001), p. 309, published by the McGraw-Hill Companies, Inc., New York, New York.
Drugs of the Future 2001,26(8), pp. 754-756 (2001), published by Prous Science, Barcelona, Spain.
Konitsiotis et al.,Neurology54, No. 8, pp. 1589-1595 (Apr. 25, 2000), published by Lippincott Williams & Wilkins, Philadelphia, PA.
Chase et al.,J. Neurol.247 [Suppl. 2]: pp. 11/36-11/42 (Apr. 2000), published by Steinkopfff Verlag, Darmstadt, Germany.
Belayev et al.,Journal of Neurotrauma,vol. 18, No. 10, pp. 1031-1038, publsihed by Mary Ann Liebert, Inc., Larchmont, NY, 2001.
Vorwerk et al.,Survey of Ophthalmology,vol. 43, Supplement 1, pp. S142-S150 (Jun. 1999), published by Elsevier Science Inc., New York, New York.
Mattson et al.,Nature,vol. 382, pp. 674-675 (Aug. 1996), published by Macmillan Magazines Ltd., London, England.
Cacabelos et al.,Drugs of Today 2000,36(7), pp. 415-499 (2000), published by Prous Science, Barcelona, Spain.
Chappel et al.,Neurology58, No. 11, pp. 1680-1682 (Jun. 11, 2002), published by Lippincott Williams & Wilkins, Philadelphia, PA.
Rzeski et al.,PNAS,vol. 98, No. 11, pp. 6372-6377 (May 22, 2001), published by the National Academy of Sciences, Washington, D.C.
Steinman,Nature Medicine,vol. 6, No. 1, pp. 15-16 (Jan. 2000), published by Nature Publishing Co., New York, New York.
Pitt et al.,Nature Medicine,vol. 6, No. 1, pp. 67-70 (Jan. 2000) published by Nature Publishing Co., New York, New York.
Smith et al.,Nature Medicine,vol. 6, No. 1, pp. 62-66 (Jan. 2000) published by Nature Publishing Co., New York, New York.
Akins et al.,Current Medical Research and Opinions,vol. 18, Suppl. 2, pp. s9-s13 (2002), published by Librapharm Limited, Newbury, Berkshire UK.
Buchan et al.,Stroke24, No. 12 [Suppl I]: I-148-I-152 (Dec. 1993), published by Lippincott Williams & Watkins, Baltimore, MD.
Mysbros et al.,Annals New York Academy of Sciences,765, 262-271 (1995), published by New York Academy of Sciences, New York, New York.
Parsons et al.,Drug News Perspect.11(9), 523-569 (1998), published by Prous Science, S.A., Barcelona, Spain.
Bräuner-Osborne et al.,J. Med. Chem.,vol. 43, No. 14, 2609-2645 (2000), published by American Chemical Society, Washington, D.C.
Gill,Cerebrovascular and Brain Metabolism Reviews,6, 225-256 (1994), published by Raven Press Publishers, New York, New York.
Meldrum,Neurology,44, Suppl. 8, S14-S23 (1994), published by Advanstar Millennium, New York, New York.
Turski et al.,J. Pharmacol. Exp. Ther.,vol. 260, No. 2, 742-747 (1992), published by Williams & Wilkins, Baltimore, MD.
Skerry et al.,Trends in Pharm. Sci.,vol. 22, No. 4, 174-181 (2001), published by Elsevier Sciences London, London, UK.
Said,Trends in Pharm. Sci.,vol. 20, 132-135 (1999), published by Elsevier Sciences London, London, UK.
Said et al.,Trends in Pharm. Sci.,vol. 22, No. 7, 344-345 (2001), published by Elsevier Sciences London, London, UK.
Visi et al.,CNS Drug Reviews,vol. 2, No. 1, 99-126 (1996), published by Neva Press, Inc., Branford, CT.
Tarnawa et al.,European Journal of Pharmacology167, 193-199 (1989), published by Elsevier Science Publishers B.V., Amsterdam, The Netherlands.
Smith et al.,European Journal of Pharmacology187, 131-134 (1990), published by Elsevier Science Publishers B.V., Amsterdam, The Netherlands.
Ouardouz et al.,Neuroscience Letters125, 5-8 (1991), published by Elsevier Scientific Publishers Ireland Ltd., Ireland.
Donevan et al.,Neuron,10, 51-59 (1993), published by Cell Press, 50 Church Street, Cambridge, Massachusetts.
Smith et al.,Nature Medicine,vol. 6, No. 1, 62-66 (2000), published by Nature America, Inc., New York, New York.
Nishizawa et al.,Advances in Experimental Medicine and Biology,Vo. 462,Advances in Bladder Research,275-281 (1999) published by Kluwer Academic/Plenum Publishers, New York, New York.
Bialer et al.,Epilepsy Research,vol. 43, 11-58 (2001), published by Elsevier Science B.V., Amsterdam, The Netherlands.
Sheardown,Brain Research,607, 189-194 (1993), published by Elsevier Science Publishers B.V., Amsterdam, The Netherlands.
Bleakman et al.,Neuropharmacologyvol. 35, No. 12, 1689-1702 (1996), published by Pergamon, Elsevier Science Ltd., Kidlington, UK.
Upton,TiPS15, 456-462 (1994), published by Elsevier Sciences, London, UK.
Randall et al.,J. Pharmacol. Exp. Ther.,129, 163-171 (1960), published by Williams & Wilkins, Baltimore, MD.
Dunham et al.,J. Am. Pharm. Assoc.,vol. 46, No. 3, 208-209 (1957), published by the American Pharmaceutical Association, Washington, D.C.
Bartus et al.,Stroke,vol. 25, No. 11, 2265-2270 (1994), published by American Heart Association, Dallas, Texas.
Sydserff et al.,British Journal of Pharmacology,vol. 114, 1631-1635 (1995), published by Stockton Press, New York, New York.
Steinman,Nature Medicine,vol. 6, No. 1, 15-16 (2000), published by Nature America Inc., New York, NY.
Werner et al.,J. Neurol. Transmiss. Suppl.,60, 375-385 (2000), published by Springer-Verlag/Wien, New York, New York.
Bjartmar et al.,Drugs of Today 2002,38(1), 17-29 (2002), published by Prous Science S.A., Barcelona, Spain.
Baker et al.,Nature,vol. 404, 84-89 (2000), published by Nature Publishing Group, London, UK.
Gijbels et al.,J. Clin. Invest.94, 2177-2182 (1994), published by The Rockefeller University Press, New York, New York.
Ábrahám Gizella
Andrási Ferenc
Berzsenyi Pál
Hámori Tamás
Kurucz István
Ivax Corporation
IVAX Drug Research Institute, Ltd.
Kifle Bruck
Steinberg Michael A.
LandOfFree
Substituted 2,3-benzodiazepine derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted 2,3-benzodiazepine derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted 2,3-benzodiazepine derivatives will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3501149